Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study.

[1]  B. Sobel,et al.  Platelet Reactivity in Coronary Ostial Blood: A Reflection of the Thrombotic State Accompanying Plaque Rupture and of the Adequacy of Anti-Thrombotic Therapy , 2001, Journal of Thrombosis and Thrombolysis.

[2]  M. Dalby,et al.  Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). , 2003, The American journal of cardiology.

[3]  J. Ware,et al.  Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[5]  K. Harre,et al.  Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). , 2002, Journal of the American College of Cardiology.

[6]  E. Topol,et al.  Platelet Glycoprotein IIb/IIIa Inhibitors: Recognition of a Two-Edged Sword? , 2002, Circulation.

[7]  R. Califf,et al.  Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. , 2002, JAMA.

[8]  R. Califf,et al.  Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. , 2002, European heart journal.

[9]  S. Sdringola,et al.  Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). , 2001, The American journal of cardiology.

[10]  M. Furman,et al.  Dissociation of Glycoprotein IIb/IIIa Antagonists From Platelets Does Not Result in Fibrinogen Binding or Platelet Aggregation , 2001, Circulation.

[11]  E. Topol,et al.  Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. , 2001, The New England journal of medicine.

[12]  M. Morice,et al.  Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. , 2001, The New England journal of medicine.

[13]  M. Simoons.  Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial , 2001, The Lancet.

[14]  David P Miller,et al.  Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. , 2001, Journal of the American College of Cardiology.

[15]  S. Steinhubl,et al.  Ticlopidine Pretreatment Before Coronary Stenting Is Associated With Sustained Decrease in Adverse Cardiac Events: Data From the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial , 2001, Circulation.

[16]  R. Jordan,et al.  Effect of Ca2+ Chelation on the Platelet Inhibitory Ability of the GPIIb/IIIa Antagonists Abciximab, Eptifibatide and Tirofiban , 2001, Thrombosis and Haemostasis.

[17]  Deepak L. Bhatt,et al.  Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists: A Meta-Analysis of Phase III Multicenter Randomized Trials , 2001, Circulation.

[18]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .

[19]  The Esprit investigators.  Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial , 2000, The Lancet.

[20]  P. Hjemdahl,et al.  Platelet-Leukocyte Cross Talk in Whole Blood , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[21]  P. Théroux,et al.  Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. , 2000, Journal of the American College of Cardiology.

[22]  S. Mousa,et al.  Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels. , 2000, Cardiovascular research.

[23]  B. Sobel,et al.  Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa. , 2000, Cardiovascular research.

[24]  Y. Matsuzawa,et al.  Association Between Ligand-Induced Conformational Changes of Integrin IIbβ3 and IIbβ3-Mediated Intracellular Ca2+ Signaling , 1998 .

[25]  C. Bode,et al.  Induction of Fibrinogen Binding and Platelet Aggregation as a Potential Intrinsic Property of Various Glycoprotein IIb/IIIa (IIbβ3) Inhibitors , 1998 .

[26]  E. Topol.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade , 1998, The Lancet.

[27]  Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. , 1998, The New England journal of medicine.

[28]  Y. Matsuzawa,et al.  Association between ligand-induced conformational changes of integrin IIbbeta3 and IIbbeta3-mediated intracellular Ca2+ signaling. , 1998, Blood.

[29]  Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. , 1998, The New England journal of medicine.

[30]  C. Bode,et al.  Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. , 1998, Blood.

[31]  L. Jennings,et al.  Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. , 1997, Circulation.

[32]  Epilog Investigators,et al.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[33]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[34]  H. Huynh,et al.  Estimation of the Box Correction for Degrees of Freedom from Sample Data in Randomized Block and Split-Plot Designs , 1976 .

[35]  J. R. O'brien.  Variability in the Aggregation of Human Platelets by adrenaline , 1964, Nature.